99mTc-(CO)3 His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab

Journal of Nuclear Medicine

Volumn 52, Issue 11, 2011, Pages 1786-1794

  Vangestel, Christel ^a   Van De Wiele, Christophe ^a   Van Damme, Nancy ^a   Staelens, Steven ^b   Pauwels, Patrick ^c   Reutelingsperger, Chris P M ^d   Peeters, Marc ^a,c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

99mTc (CO)3 his annexin A5; Anti VEGF; Chemotherapy delivery; Colorectal cancer; Vascular normalization

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BEVACIZUMAB; CARBON TRIOXIDE HISTIDINE ANNEXIN A5 TC 99M; CASPASE 3; IRINOTECAN; PIMONIDAZOLE; SODIUM CHLORIDE; TRACER; UNCLASSIFIED DRUG; (99)MTC (CO)(3) HIS ANNEXIN A5; (99)MTC-(CO)(3) HIS-ANNEXIN A5; ACTIN; ANGIOPOIETIN 1; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CD31 ANTIGEN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; LIPOCORTIN 5; MONOCLONAL ANTIBODY; TECHNETIUM COMPLEX; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MICRO SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; MONOTHERAPY; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CELL HYPOXIA; CELL TRANSFORMATION; COLORECTAL TUMOR; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SCINTISCANNING; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION;

ACTINS; ANGIOPOIETIN-1; ANIMALS; ANNEXIN A5; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CASPASE 3; CELL HYPOXIA; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; MICE; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOTECHNETIUM COMPOUNDS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSCRIPTION, GENETIC; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80455129817     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.092650     Document Type: Article

References (20)

1. Presta LG, Chen H, O'Conner SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599. (Pubitemid 27441066)
2. Tonra JR, Hicklin DJ. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. Immunol Invest. 2007;36:3-23. (Pubitemid 46024914)
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
5. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62. (Pubitemid 40093472)
6. 99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells. Nucl Med Biol. 2010;37:965-975.
7. 3 His-annexin A5 in a colorectal cancer xenograft model. Mol Imaging. In press.
8. van der Have F, Vastenhouw B, Ramakers RM, et al. U-SPECT-II: an ultra-highresolution device for molecular small-animal imaging. J Nucl Med. 2009;50: 599-605.
9. Blankenberg FG, Katsikis PD, Tait JF, et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med. 1999;40:184-191. (Pubitemid 29044190)
10. 99mHYNIC- annexin V: a potential for the in-vivo detection of apoptosis. Eur J Nucl Med Mol Imaging. 1999;26:1251-1258.
11. 99mTc-annexin V and its biological evaluation for in vivo imaging of apoptosis after photodynamic therapy. J Nucl Med. 2003;44:650-656.
12. Myers AL, Williams RF, Ng CY, Hartwich JE, Davidoff AM. Bevacizumabinduced tumor vessel remodelling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg. 2010;45:1080-1085.
13. Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol. 2010;136:1201-1211.
14. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGFspecific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-147. (Pubitemid 38524883)
15. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994;13:139-168. (Pubitemid 24220002)
16. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer. 2003;88:1979-1986. (Pubitemid 36829677)
17. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64:3731-3736. (Pubitemid 38697278)
18. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodelling of the vasculature in neuroblastoma xenograft results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007; 13:3942-3950. (Pubitemid 47037602)
19. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685-693. (Pubitemid 36749217)
20. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoetin-1 and matrix metalloproteinases. Cancer Cell. 2004;6: 553-563. (Pubitemid 40017699)